Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- TW
- YU
Lists including Katie
Investments
Veralox Therapeutics
Total Funding: $46M
Jaguar Gene Therapy
Total Funding: $140M
Biolinq
Total Funding: $110M
DiogenX
Total Funding: $42M
i2o Therapeutics
Total Funding: $4M
Repertoire Immune Medicines
Total Funding: $210M
IMTherapeutics
Total Funding: $10M
Work Experience
Board Member
2025
2023
Board Member
2023
Board Member
2021
2018 - 2024
Managing Director
2018 - 2024
The Fund is a venture philanthropy fund committed to accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic equity investments. While independently managed, the Fund is affiliated with JDRF, the leading global organization funding T1D research. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance cures and therapies into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.
2021 - 2024
Board Observer
2021 - 2024
2020 - 2024
Board Member
2020 - 2024
2020 - 2024
Board Observer
2020 - 2024
2019 - 2024
Board Observer
2019 - 2024
2019 - 2024
Board Member
2019 - 2024
2018 - 2024
Board Observer
2018 - 2024